Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
The recent $114m Series B round raised by Semma Therapeutics Inc. reflects two positive trends about the venture capital environment for biopharmaceuticals companies – both the number of companies and the amount of money raised by new and early-stage firms are rising.
Cambridge, Mass.-based Semma launched in 2015 with a significant amount of venture capital – a $44m Series A round to...
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.
